跳至主要内容
临床试验/CTRI/2020/09/028055
CTRI/2020/09/028055进行中(未招募)2 期

A multicenter randomized control trial to compare the efficacy and safety of single dose versus two doses of rituximab in patients 2-12 years of age with steroid dependant or frequently relapsing nephrotic syndrome who has failed atleast two steroid sparing agents - the RIT-TIC trial (RITuximab in nephroTIC)

Institute of Child Health Kolkata AND Medical College Kolkata0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with idiopathic nephrotic syndrome with steroid dependence or frequent relapses who has failed at least two steroid sparing agents, last one being failed in previous 3 months
  • 2. Patients is in remission state of the disease
  • 3. Legal guardian is willing to give informed written consent

排除标准

  • 1.Prior therapy with rituximab in last one year
  • 2.Historical steroid resistance in last one year
  • 3.Hepatitis B and C serology positive
  • 4.Acute or chronic active infection
  • 5.Chronic lung disease or uncontrolled asthma
  • 6.Leucopenia or thrombocytopenia
  • 7.Expected rituximab first infusion date less than 4 weeks from a live vaccination
  • 8.Documented intolerance to mycophenolate in past
  • 9.eGFR < 60 ml/min/1.73m2
  • 10.Regular follow-up not feasible

研究者

发起方
Institute of Child Health Kolkata AND Medical College Kolkata

相似试验